Last week, ML Strategies released an Advisory providing a comprehensive review of the sweeping health care legislation recently released by the Massachusetts Senate.

Earlier this month, Mintz Levin's Health Care Enforcement Defense Group published its most recent Health Care Qui Tam Update that looks at 23 health care-related qui tam cases unsealed in June 2017.

This lack of uniformity imposes an ongoing challenge for telemedicine providers.

Earlier this month, two states – Maryland and Nevada – passed legislation aimed at controlling drug prices. The two laws are being touted by proponents as decisive action against pharmaceutical manufacturers.

Last week, the Congressional Budget Office (CBO) concluded that a key piece of telehealth legislation, the CHRONIC Care Act of 2017, would not, overall, increase or decrease Medicare spending.

The Affordable Care Act created the Innovation Center within CMS to test innovative payment and service delivery models.

In 2016 and now in early 2017, state legislatures and regulatory boards continue to enact laws and rules setting telemedicine practice standards.

Last week, the Medicare Payment Advisory Commission (the "Commission") debated a package of policy reforms that would change the way Medicare reimburses physicians for Medicare Part B drugs.

More than two years since issuing the proposed rule, the HHS Office of the Inspector General issued the long-awaited and highly anticipated final rule that provides amendments to the Anti-Kickback Statute regulatory safe harbors ...

A Trump victory was not the only surprise on election night. California's drug pricing initiative, which would have required state agencies to negotiate drug prices at least as low as those paid...

There has always been the need for health care providers to be vigilant in choosing and monitoring claims submitted by billing companies on their behalf.

The GAO found that manufacturer drug coupon programs for privately insured patients could potentially cause the Medicare Part B program to overspend on certain high-cost Part B drugs.

In another procedural defeat for the Texas Medical Board over its embattled telemedicine rule, last week, a federal judge held that the Board waited too long to request certification of appeal to the Fifth Circuit.

As we previously reported, in 2015 and early 2016, bills and voter initiatives were introduced in several states that would impose drug pricing controls and transparency requirements on pharmaceutical manufacturers.

On June 17, the Texas Medical Board ("Board") filed a brief with the Fifth Circuit Court of Appeals reiterating that the Board's rulemaking processes are protected under the state action immunity doctrine...